Local Anaesthetics Combined with Vasoconstrictors in Controlled Hypertensive Patients Undergoing Dental Procedures: Systematic Review and Meta-Analysis / Uso de Anestésicos Locales con Vasoconstrictor en Pacientes con Hipertensión Controlada Durante la Atención Odontológica: Una Revisión Sistemática y Metaanálisis

The aim of this systematic review is to assess the safety of local anaesthetics (LA) combined with vasoconstrictors (VC) for patients with controlled hypertension undergoing dental procedures. A comprehensive search strategy were used to identify all relevant randomized controlled trials (RCTs) that evaluated the effect of LA combined with VC. All searches covered the period from 1990 to February 2021. We performed a meta-analysis using random-effect models and assessed overall certainty in evidence using GRADE approach. Our search strategy yielded 1262 references. Finally, seven randomised trials were included, but only three were included in the meta-analysis. The use of LA with VC may result in little to no difference in the heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP), but the certainty of the evidence was assessed as low. Death, stroke, acute myocardial infarction, need for hospitalization, pain and bleeding were not reported by the included studies. The hemodynamic changes using VC do not imply an increased risk of occurrence of adverse cardiovascular events. The use of VC could even be recommendable considering their multiple advantages.

El objetivo de esta revisión sistemática es evaluar la seguridad del uso de anestésicos locales (AL) combinados con vasoconstrictor (VC) en pacientes con hipertensión controlada durante procedimientos dentales. Se realizó una estrategia de búsqueda para identificar todos los estudios clínicos aleatorizados (ECA) relevantes que evaluaban el efecto del AL combinado con VC. Todos los estudios fueron del periodo entre 1990 a febrero del 2021. Se realizó un meta-análisis usando modelos de efecto aleatorizado y una revisión de la certeza de la evidencia usando el método GRADE. Nuestra estrategia de búsqueda arrojó 1262 referencias. Finalmente, siete estudios clínicos aleatorizados fueron incluidos, de los cuales tres fueron incluidos en el meta-análisis. El uso de AL con VC produce una pequeña a ninguna diferencia en el pulso cardiaco, presión sistólica y diastólica, pero la certeza de la evidencia fue baja. Muerte, infarto agudo al miocardio, accidente cerebrovascular, necesidad de hospitalización, dolor y hemorragia no fueron reportados en los estudios incluidos. Los cambios hemodinámicos en el uso de VC no implican un aumento de riesgo de ocurrencia de efectos adversos cardiovasculares. El uso de VC puede ser recomendable considerando sus múltiples ventajas.

Risk analysis and preventive strategies of implant placement in patients with hypertension / 中华口腔医学杂志

Recently, among the edentulous patients who undergo dental implants, the proportion of hypertensive patients remains high, which poses a greater challenge for clinicians to operate and to maintain the therapeutic effect. The present review comprehensively summarized clinical researches about the adverse effects on dental implants, outlined molecular mechanisms of the positive effects of various antihypertensive drugs on bone metabolism, and proposed that clinicians should select preventive strategies during preoperative and intraoperative procedures according to the blood pressure of patients with hypertension.

Repercussões em longo prazo da derivação gástrica em Y de Roux em população de baixa renda: avaliação após dez anos de cirurgia / Long-term repercussions of Roux-en-Y gastric bypass in a low-income population: assessment ten years after surgery

RESUMO Objetivo: avaliar a evolução ponderal, nutricional e a qualidade de vida de pacientes de baixa renda, após dez anos de derivação gástrica em Y de Roux (DGYR). Métodos: estudo longitudinal, retrospectivo e descritivo, que avaliou a perda do excesso de peso, o reganho de peso, a evolução da hipertensão arterial, do diabetes mellitus tipo 2, da anemia e da hipoalbuminemia em 42 pacientes de classes sociais D e E submetidos à DGYR. A qualidade de vida foi avaliada através do Bariatric Analysis and Reporting Outcome System (BAROS). Resultados: dos 42 pacientes, 68,3% se definiram como não praticantes de atividade física regular, e somente 44,4% e 11,9% tinham acompanhamento médico e nutricional regulares, respectivamente. Foi encontrada média da perda do excesso de peso de 75,6%±12 (IC=71,9-79,4) e perda ponderal insuficiente apenas em um paciente. O reganho ponderal médio foi de 22,3%±16,2 (IC=17,2-27,3), com 64,04% da amostra apresentando reganho maior do que 15% do peso mínimo. 52,3% da amostra apresentou anemia após dez anos de cirurgia e 47,6% deficiência de ferro. Hipoalbuminemia foi encontrada em 16,6% da amostra. Houve remissão da HAS em 66% e do diabetes mellitus tipo 2 em 50%. O BAROS demonstrou melhora na qualidade de vida em 85,8% dos pacientes. Conclusão: pudemos observar, em uma população com diversas limitações socioeconômicas, que a DGYR manteve resultados satisfatórios quanto à perda peso, mas o seguimento ineficiente pode comprometer o resultado final, especialmente no que diz respeito às deficiências nutricionais.

ABSTRACT Objective: to evaluate the weight, nutritional and quality of life of low-income patients after ten years of Roux-en-Y gastric bypass (RYGB). Methods: we conducted a longitudinal, retrospective and descriptive study evaluating the excess weight loss, weight regain, arterial hypertension, type 2 diabetes mellitus, anemia and hypoalbuminemia in 42 patients of social classes D and E submitted to RYGB. We assessed quality of life through the Bariatric Analysis and Reporting Outcome System (BAROS). Results: of the 42 patients, 68.3% defined themselves as doing non-regular physical activity, and only 44.4% and 11.9% had regular medical and nutritional follow-up, respectively. We found a mean excess weight loss of 75.6%±12 (CI=71.9-79.4), and in only one patient there was insufficient weight loss. The mean weight loss was 22.3%±16.2 (CI=17.2-27.3) with 64.04% of the sample presenting regain greater than 15% of the minimum weight; 52.3% of the sample presented anemia after ten years of surgery and 47.6%, iron deficiency. We found hypoalbuminemia in 16.6% of the sample. There was remission of hypertension in 66%, and of type 2 diabetes mellitus, in 50%. BAROS showed an improvement in the quality of life of 85.8% of the patients. Conclusion: in a population with different socioeconomic limitations, RYGB maintained satisfactory results regarding weight loss, but inefficient follow-up may compromise the final result, especially with regard to nutritional deficiencies.

Effects and Mechanisms of Radiofrequency Ablation of Renal Sympathetic Nerve on Anti-Hypertension in Canine / Efeitos e Mecanismos da Denervação Simpática Renal por Radiofrequência na Anti-Hipertensão em Cães

Abstract Background: Radiofrequency ablation of renal sympathetic nerve (RDN) shows effective BP reduction in hypertensive patients while the specific mechanisms remain unclear. Objective: We hypothesized that abnormal levels of norepinephrine (NE) and changes in NE-related enzymes and angiotensinconverting enzyme 2 (ACE2), angiotensin (Ang)-(1-7) and Mas receptor mediate the anti-hypertensive effects of RDN. Methods: Mean values of systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) were assessed at baseline and follow-up. Plasma and renal norepinephrine (NE) concentrations were determined using highperformance liquid chromatography with electrochemical detection, and levels of NE-related enzyme and ACE2-Ang(1-7)- Mas were measured using real time PCR, Western blot and immunohistochemistry or Elisa in a hypertensive canine model fed with high-fat diet and treated with RDN. The parameters were also determined in a sham group treated with renal arteriography and a control group fed with normal diet. Results: RDN decreased SBP, DBP, MAP, plasma and renal NE. Compared with the sham group, renal tyrosine hydroxylase (TH) expression was lower and renalase expression was higher in the RDN group. Compared with the control group, renal TH and catechol-o-methyl transferase (COMT) were higher and renalase was lower in the sham group. Moreover, renal ACE2, Ang-(1-7) and Mas levels of the RDN group were higher than those of the sham group, which were lower than those of the control group. Conclusion: RDN shows anti-hypertensive effect with reduced NE and activation of ACE2-Ang(1-7)-Mas, indicating that it may contribute to the anti-hypertensive effect of RDN.

Resumo Fundamentos: A denervação simpática renal por radiofrequência (DSR) mostra redução eficaz da pressão arterial (PA) de pacientes hipertensos, ainda que os mecanismos específicos permaneçam obscuros. Objetivo: Fizemos a hipótese de que níveis alterados de noradrenalina (NA) e mudanças nas enzimas relacionadas à NA e enzima conversora de angiotensina 2 (ECA-2), angiotensina (Ang)-(1-7) e receptor Mas são mediadores dos efeitos antihipertensivos da DSR. Métodos: Foram avaliados os valores médios de pressão arterial sistólica (PAS), pressão arterial diastólica (PAD) e pressão arterial média (PAM) no início e durante o seguimento. Foram medidas as concentrações plasmática e renal de noradrenalina (NA) por cromatografia líquida de alta eficiência com detecção eletroquímica, e os níveis de enzima relacionada à NA e ECA2-Ang-(1-7)-Mas através de PCR em tempo real, Western blot e imunohistoquímica ou Elisa em um modelo canino de hipertensão que recebeu ração rica em gordura e foi tratado com DSR. Os parâmetros também foram determinados em um grupo de cirurgia simulada submetido à arteriografia renal e em um grupo controle que recebeu dieta normal. Resultados: DSR causou diminuição da PAS, PAD, PAM e das concentrações plasmática e renal de NA. Em comparação ao grupo placebo, a expressão da tirosina hidroxilase (TH) renal foi menor e a da renalase foi maior no grupo DSR. Em comparação ao grupo controle, os níveis de TH renal e de catecol-o-metil-transferase (COMT) foram maiores e os de renalase foram menores no grupo cirurgia simulada. Além disso, os níveis renais de ECA2, Ang-(1-7) e Mas foram maiores no grupo DSR do que no grupo cirurgia simulada, que, por sua vez, foram menores do que no grupo controle. Conclusões: A DSR mostra efeitos anti-hipertensivos com redução da NA e ativação da ECA2-Ang-(1-7)-Mas, o que indica que pode contribuir com o efeito anti-hipertensivo da DSR.

Declaración ante los resultados del ensayo clínico Symplicity HTN 3. Grupo de estudio de la hipertensión arterial resistente / Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensión arterial resistente

La denervación de las arterias renales ha sido una alternativa para el tratamiento de la hipertensión arterial resistente. Los estudios Symplicity HTN 1 y 2 mostraron en grupos pequeños y no controlados disminuciones de la presión sistólica hasta de 30 mm Hg. Este entusiasmo ha sido opacado por el estudio Symplicity HTN 3, ensayo clínico aleatorizado y controlado con un procedimiento placebo. Sorprendentemente, los resultados sugirieron que la denervación renal tuvo un efecto similar al del placebo, aunque en el análisis de subgrupos preespecificados los pacientes que no eran de raza negra, los menores de 65 años y los que tenían función renal normal tuvieron una reducción de la presión arterial sistólica estadísticamente significativa. Esta es una evaluación crítica de los resultados del Symplicity HTN 3 y propone posibles explicaciones para estos. Además, declara la postura de nuestro grupo y las acciones futuras.

Renal artery denervation has shown to be an effective treatment for resistant hypertension. Symplicity HTN 1 and 2 trials showed in small and uncontrolled groups, significant systolic blood pressure reductions down to 30 mm Hg. Symplicity HTN-3, a double blind, randomized, placebo controlled clinical trial shaded this initial enthusiasm. Surprisingly, their results showed that renal denervation has a similar effect to placebo. Pre-specified subgroup analysis showed that non-black race individuals, younger than 65 years and with normal renal function, had a statistically significant systolic blood pressure decrease. This manuscript critically appraises the Symplicity HTN-3 trial, proposing possible explanations for the results. Also declares our group position and future actions regarding renal denervation.

Nephron-sparing surgery for treatment of reninoma: a rare renin secreting tumor causing secondary hypertension

Main findings A 25-year-old hypertensive female patient was referred to our institution. Initial workup exams demonstrated a 2.8 cm cortical lower pole tumor in the right kidney. She underwent laparoscopic partial nephrectomy without complications. Histopathologic examination revealed a rare juxtaglomerular cell tumor known as reninoma. After surgery, she recovered uneventfully and all medications were withdrawn. Case hypothesis Secondary arterial hypertension is a matter of great interest to urologists and nephrologists. Renovascular hypertension, primary hyperadosteronism and pheocromocytoma are potential diagnosis that must not be forgotten and should be excluded. Although rare, chronic pyelonephritis and renal tumors as rennin-producing tumors, nephroblastoma, hypernephroma, and renal cell carcinoma might also induce hypertension and should be in the diagnostic list of clinicians. Promising future implications Approximately 5% of patients with high blood pressure have specific causes and medical investigation may usually identify such patients. Furthermore, these patients can be successfully treated and cured, most times by minimally invasive techniques. This interesting case might expand knowledge of physicians and aid better diagnostic care in future medical practice. .

Denervação Renal com Cateter Irrigado em Hipertensos Resistentes: Uma Estratégia Promissora? / Renal Denervation Using an Irrigated Catheter in Patients with Resistant Hypertension: A Promising Strategy?

Fundamento: A hipertensão arterial sistêmica constitui importante problema de saúde pública e significativa causa de mortalidade cardiovascular. A elevada prevalência e as reduzidas taxas de controle tensional despertaram o interesse por estratégias terapêuticas alternativas. A denervação simpática renal percutânea surgiu como perspectiva no tratamento de hipertensos resistentes. Objetivo: Avaliar a factibilidade e a segurança da denervação renal com cateter irrigado. Métodos: Dez hipertensos resistentes foram submetidos ao procedimento. O desfecho primário foi a segurança, avaliada por eventos adversos periprocedimento, função renal e anormalidade vascular renal aos 6 meses. Os desfechos secundários constituíram mudanças na pressão arterial (consultório e monitorização ambulatorial) e no número de anti-hipertensivos aos 6 meses. Resultados: A média de idade foi de 47,3 (± 12) anos, 90% eram mulheres. No primeiro caso, houve dissecção de artéria renal causada por trauma da bainha, fato que não se repetiu após ajuste técnico, demonstrando efeito da curva de aprendizado. Nenhum caso de trombose/infarto renal ou óbito foi reportado. Não se observou elevação dos níveis séricos de creatinina durante o seguimento. Aos 6 meses, diagnosticou-se um caso de estenose significativa de artéria renal, sem repercussão clínica. A denervação renal reduziu a pressão arterial de consultório, em média, em 14,6/6,6 mmHg (p = 0,4 tanto para pressão arterial sistólica como para a diastólica). A redução média da pressão arterial pela monitorização ambulatorial foi de 28/17,6 mmHg (p = 0,02 e p = 0,07 para pressão arterial sistólica e diastólica, ...

Background: Systemic hypertension is an important public health problem and a significant cause of cardiovascular mortality. Its high prevalence and the low rates of blood pressure control have resulted in the search for alternative therapeutic strategies. Percutaneous renal sympathetic denervation emerged as a perspective in the treatment of patients with resistant hypertension. Objective: To evaluate the feasibility and safety of renal denervation using an irrigated catheter. Methods: Ten patients with resistant hypertension underwent the procedure. The primary endpoint was safety, as assessed by periprocedural adverse events, renal function and renal vascular abnormalities at 6 months. The secondary endpoints were changes in blood pressure levels (office and ambulatory monitoring) and in the number of antihypertensive drugs at 6 months. Results: The mean age was 47.3 (± 12) years, and 90% of patients were women. In the first case, renal artery dissection occurred as a result of trauma due to the long sheath; no further cases were observed after technical adjustments, thus showing an effect of the learning curve. No cases of thrombosis/renal infarction or death were reported. Elevation of serum creatinine levels was not observed during follow-up. At 6 months, one case of significant renal artery stenosis with no clinical consequences was diagnosed. Renal denervation reduced office blood pressure levels by 14.6/6.6 mmHg, on average (p = 0.4 both for systolic and diastolic blood pressure). Blood pressure levels on ambulatory monitoring decreased by 28/17.6 mmHg (p = 0.02 and p = 0.07 for systolic and diastolic blood pressure, respectively). A mean reduction of 2.1 antihypertensive drugs was observed. Conclusion: Renal denervation is feasible and safe in the treatment of resistant systemic arterial hypertension. Larger studies are required to confirm our findings. .

Control of hypettension after roux-en-y gastric bypass among obese diabetic patients / Controle da hipertensão arterial após bypass gástrico em Y-de-Roux em obesos diabéticos

Context Hypertension is a common disorder in general practice and has a widely known association with type 2 diabetes mellitus. Low adhesion to clinical treatment may lead to poor results. Obesity surgery can bring early and relevant resolution rates of both morbidities. Objective To describe hypertension evolution after Roux-en-Y gastric bypass in patients with type 2 diabetes mellitus. Method Descriptive observational study designed as a historical cohort of 90 subjects with hypertension and diabetes who underwent Roux-en-Y gastric bypass and were evaluated before and after surgery. Results It was observed a hypertension resolution rate of 85.6% along with markedly decrease in anti-hypertensive usage. Mean resolution time was 3.2 months. Resolution was associated with homeostasis model assessment – insulin resistance, preoperative fasting insulin, anti-hypertensive usage, hypertension time, body mass index and percentage of weight loss. Resolution of hypertension was not statistically associated with diabetes remission within this sample. Conclusion Roux-en-Y gastric bypass was a safe and effective therapeutic tool to achieve hypertension resolution in patients who also had diabetes mellitus. .

Contexto A hipertensão arterial é uma patologia frequente na prática clínica e sua associação ao diabetes mellitus tipo 2 é amplamente conhecida. A baixa adesão ao tratamento clínico comumente leva a resultados precários. A cirurgia bariátrica é capaz de promover precocemente índices elevados de resolução de ambas as morbidades. Objetivo Descrever a evolução da hipertensão arterial após o bypass gástrico em Y-de-Roux em indivíduos diabéticos. Métodos Estudo descritivo observacional de coorte histórica envolvendo 90 indivíduos com hipertensão e diabetes que foram submetidos ao bypass gástrico em Y-de-Roux, avaliados antes e após o procedimento. Resultados Foi observado índice de resolução da hi­pertensão de 85.6% associado a grande redução na utilização de anti-hipertensivos. O tempo médio de resolução foi de 3.2 meses. A resolução esteve associada ao modelo de avaliação homeostática (HOMA) – resistência insulínica, insulina basal pré-operatória, uso de anti-hipertensivos, tempo de hipertensão, índice de massa corpórea e percentual de perda do excesso de peso. A resolução da hipertensão não foi associada estatisticamente à remissão do diabetes na amostra estudada. Conclusão O bypass gástrico em Y-de-Roux foi uma opção terapêutica segura e eficiente para levar à resolução da hipertensão em pacientes diabéticos. .

Denervación del sistema nervioso simpático renal: una nueva alternativa para tratar la hipertensión: reporte de un caso / Denervation of the renal sympathetic nervous system: a new alternative for treating hypertension: a case report

La presión arterial (PA) que persiste sobre140/90mmHg, aun cuando se utilicen tres o más fármacos antihipertensivos a dosis máximas toleradas, incluyendo un diurético, es definida como hipertensión arterial (HTA) resistente. La hiperactividad del sistema nervioso simpático renal influye críticamente en su fisiopatología. El año 2009 se publicó la denervación simpática o simpatectomía renal (DSR), técnica prometedora para tratar la hipertensión resistente, mediante radiofrecuencia. No existen reportes de su uso en Chile. El objetivo del caso es comunicar una nueva alternativa para tratarla HTA resistente, en términos del control de la PA. PRESENTACIÓNDEL CASO: Paciente varón, 64 años, con antecedentes de HTA resistente, infarto al miocardio y accidente vascular encefálico recuperado, fue evaluado para valorar posibilidad de realizar DSR, por persistencia de HTA a pesar de tratamiento con 4 fármacos hipotensores. Se citó en agosto del 2012 al Hospital Las Higueras, Talcahuano, constatándose asintomático,PA: 161/85mmHg, sin otras alteraciones al examen físico. Exámenes laboratorio normales. Se decidió intervenir un mes después, efectuándose el procedimiento sin complicaciones.PA: día post intervención 108/59mmHg; control a dos semanas148/87mmHg, sin usar hipotensores. DISCUSIÓN: La DSR puede reducir sustancialmente la PA (–27/–17mmHg al año). En Chile, existe una alta prevalencia de HTA y sólo un bajo porcentaje logra normalizar su PA mediante terapia no farmacológica y/o farmacológica. En este caso, se realizó seguimiento con control de PA a los tres, seis, nueve y doce meses, encontrándose valores significativamente menores. Actualmente mantiene su PA bajo control con 2 fármacos hipotensores...

A blood pressure (BP) that remains over140/90mmHg despite the use of three or more antihypertensive drugs at maximum tolerated doses, including a diuretic, is defined as resistant hypertension (HT). The hyperactivity of the sympathetic nervous system critically influences renal pathophysiology. In 2009, a publication showed that sympathetic renal denervation (SRD) or renal sympathectomy, was a promising radiofrequency technique for the treatment of resistant hypertension, with no reports in Chile. The aim of this case is to present a new alternative for the treatment of resistant hypertension, through the control of BP. CASE REPORT: A 64-yearoldmale, with a history of resistant hypertension, myocardial infarction and stroke without squeal, was evaluated at Las Higueras Hospital, Talcahuano, in august 2012, to assess the possibility of RSD, for the treatment of his resistant hypertension.The patient was asymptomatic with no findings in physical examination, but BP 161/58 mmHg. Laboratory results were normal. The procedure was performed, one month later, without complications. The day next to intervention BP 108/59 mmHg. Two weeks later control BP 148/87 mmHg without antihypertensive drugs. DISCUSSION: SDR can significantly reduce BP(-27/-17mmHg per year). In Chile, there is a high prevalence of hypertension and a low percentage of patients normalizes BPwith non-pharmacological and/or pharmacological treatment. The patient was controlled at three, six, nine and twelve month post SDR, with BP values significantly lower than pre-SDR. At present, patient BP is under management with two antihypertensive drugs...

Desnervação simpática renal no tratamento da hipertensão arterial resistente : perspectivas atuais / Renal sympathetic denervation for resistant hypertension treatment : current perspectives

Os autores revisam o conceito de hipertensão arterial resistente e o envolvimento do sistema nervoso simpático na hipertensão arterial como base racional para a técnica de desnervação simpática renal (DSR), realizada por via percutânea. A presente revisão é resultado de uma busca ativa de artigos científicos com o nome "renal denervation" na base de dados Medline e PubMed. A técnica e os dispositivos empregados no procedimento são apresentados, bem como os resultados clínicos em seis, 12 e 24 meses após a intervenção com o cateter Symplicity. Observam-se reduções expressivas e progressivamente maiores da PAS e PAD após a DSR. A taxa de complicações foi mínima. Novos dispositivos para a DSR e respectivos estudos clínicos em andamento são citados. Em conclusão, a DSR apresenta-se como um procedimento efetivo e seguro para a abordagem da hipertensão arterial resistente. Resultados de estudos em andamento e tempo maior de seguimento desses pacientes são aguardados para confirmar os resultados iniciais e colocar em perspectiva a ampliação da utilização do procedimento na abordagem da hipertensão arterial.

The authors review the concept of resistant hypertension and the involvement of the sympathetic nervous system in hypertension as a rational basis for the technique of renal sympathetic denervation (RSD) performed percutaneously. This revision is the result of an active search for scientific articles with the term "renal denervation" in the Medline and PubMed databases. The techniques and devices used in the procedure are presented, as well as clinical outcomes at six, 12 and 24 months after the intervention with the Symplicity catheter. Significant decreases and progressively higher reductions of systolic and diastolic blood pressure were observed after RSD. The complication rate was minimal. New devices for RSD and its ongoing clinical studies are cited. In conclusion, the RSD presents itself as an effective and safe approach to resistant hypertension. Results from ongoing studies and longer follow-up of these patients are expected to confirm the initial results and put into perspective the expansion of the procedure use in hypertension approach.

Effect of renal denervation procedure on left ventricular hypertrophy of hypertensive rats and its mechanisms / Efeito da denervação renal na hipertrofia do ventrículo esquerdo de ratos hipertensos e seu mecanismo

PURPOSE: To investigate the effect of renal denervation (RDN) on the blood pressure, left ventricular hypertrophy and myocardial expression of TLR4/NF-κB in spontaneously hypertensive rats (SHR). METHODS: A total of 36 SHR were randomly assigned into control group (D0), RDN group (D) and sham group (S). 12 WKY rats of same age served as controls (WKY group). Rats in the D0 and WKY groups were sacrificed, but rats in the D and S group were sacrificed at one week and six weeks after surgery. The heart was collected and the left ventricle weighted followed by calculation of left ventricular mass index (LVMI). RESULTS: In the D0 group, the blood pressure, LVMI and protein expression of TLR4, NF-κB, TNF-α and IL-6 in the myocardium were markedly higher than that in the WKY group (p<0.05). In the D1 and D2 group, the LVMI, NE and protein expression of TLR4, NF-κB, TNF-α and IL-6 in the myocardium were significantly reduced (p<0.05). CONCLUSION: Renal denervation can significantly delay the progression of left ventricular hypertrophy in spontaneously hypertensive rats, which may be attributed to the not only the suppression of sympathetic activity and attenuation of pressure load but the improvement of myocardial immuno-inflammation.

OBJETIVO: Investigar o efeito da denervação renal na pressão sanguínea, na hipertrofia do ventrículo esquerdo e a expressão miocárdica de TLR4/NF-kB em ratos espontaneamente hipertensos. MÉTODOS: Trinta e seis SHR ratos foram aleatoriamente distribuídos em grupo controle, grupo denervação renal (D) e grupo sham(S). 12 WKY ratos de mesma idade serviram de controle. Os ratos controles foram sacrificados, mas os ratos com denervação renal e sham foram sacrificados uma semana e seis semanas após a cirurgia. O coração foi retirado e o ventrículo esquerdo pesado seguido pelo cálculo da massa ventricular (LVMI). RESULTADOS: No grupo DO, a pressão sanguínea, LVMI e a expressão proteica de TLR4, NF-κB, TNF-α e IL-6, no miocárdio foram marcadamente maiores do que o grupo WKY (p<0,05). Nos grupos D1 e D2, o LVMI, NE e a expressão proteica de TLR4, NF-κB, TNF-α e IL-6 no miocárdio foi significantemente reduzido (p<0,05). CONCLUSÃO: A denervação renal pode significantemente retardar a progressão da hipertrofia ventricular esquerda em ratos espontaneamente hipertensos, o que pode ser atribuído não apenas pela supressão da atividade simpática e atenuação da pressão, mas pela melhora na imunoinflamação miocárdica.

Anestesia para suprarrenalectomia em pacientes com feocromocitoma bilateral: relato de dois casos e considerações sobre o tema / Anesthesia for adrenalectomy in patients with bilateral pheochromocytoma: a two-case report and remarks on the topic

O feocromocitoma é um tumor raro, sendo sua incidência estimada em um a dois casos por 100.000 adultos. Ocorrem em aproximadamente 0,1% da população hipertensa, sendo importante causa de hipertensão arterial grave corrigível. O tratamento cirúrgico, com retirada total de todos os focos de tecido tumoral, constitui-se no único tratamento definitivo do feocromocitoma e pode ser realizado por via aberta ou videolaparoscópica. O preparo pré-operatório é realizado com o objetivo de tratar a hipertensão arterial, evitar a ocorrência de paroxismos e de corrigir uma eventual hipovolemia. Se isso não for feito, os pacientes correm o risco de desenvolver hipotensão importante e mesmo choque hipovolêmico após a retirada do tumor e consequente desaparecimento da vasoconstrição. Durante o procedimento cirúrgico, seja ele aberto ou laparoscópico, a pressão arterial média, a pressão venosa central, o ritmo e a frequência cardíaca devem ser continuamente monitorizados. As reações hipertensivas que acontecem, inevitavelmente, durante o manuseio cirúrgico do tumor devem ser tratadas com a infusão endovenosa de drogas de ação imediata, como o alfa-bloqueador adrenérgico fentolamina ou o vasodilatador de ação direta, nitroprussiato de sódio. Taquicardia e arritmias devem ser tratadas com a administração endovenosa de beta-bloqueadores. A administração de volume, principalmente após a retirada do tumor, deve ser efetuada quando os níveis de pressão arterial média e de pressão venosa central, associados a parâmetros clínicos e laboratoriais, indicarem a existência de hipovolemia. A maioria dos pacientes com hipotensão no pós-operatório responde bem à administração de volume, sendo raramente necessárias drogas vasoativas. Outra ocorrência possível, mas menos provável, nas primeiras 24 a 48 horas do pós-operatório é a hipoglicemia, sendo recomendado controle de glicemia capilar nas primeiras 48 horas do pós-operatório. O objetivo deste artigo é apresentar dois casos de ressecção de feocromocitoma realizados em nosso serviço e com diferentes evoluções e discutir os cuidados perioperatórios para esse tipo de cirurgia.(AU)

Pheochromocytoma is a rare tumor with estimated incidence of 2 cases per 100,000 adults. It affects approximately 0.1% of the hypertensive population, and is an important cause of a correctable form of severe arterial hypertension. Surgery to remove every focus of tumoral tissue is the only definitive treatment and can be performed either by incision or videolaparoscopy. Preoperative care is provided to treat arterial hypertension, avoid paroxysms, and correct eventual hypovolemia. Otherwise, patients may develop considerable hypotension and even hypovolemic shock after tumor removal and eventually loss of vasoconstriction. Irrespective of the type of surgery, mean arterial pressure, central venous pressure, and heart rhythm and rate must be continuously monitored during procedures. The hypertensive reactions that inevitably take place during surgical handling of the tumor must be treated with intravenous infusion of rapid acting drugs, such as the adrenergic alpha-blocker phentolamine or the direct action vasodilator sodium nitroprusside. Tachycardia and arrhythmia must be treated with intravenous infusion of beta-blockers. Administration of volume, especially after tumor removal, must be carried out when the levels of mean arterial pressure and central venous pressure, associated with clinical and laboratorial parameters, point to hypovolemia. Most patients with postoperative hypotension react well to the administration of volume, and vasoactive drugs are rarely needed. It is also possible, although usually unlikely, that patients have hypoglycemia in the first 24-48 hours after surgery; capillary blood glucose testing is thus recommended within the first 48 hours after surgery. This paper aims to report on two cases of pheochromocytoma resection carried out at our health care center, which progressed differently, and to discuss perioperative care issues for this type of surgery.(AU)

Evolución de comorbilidades metabólicas asociadas a obesidad después de cirugía bariátrica / Effects of gastric bypass on weight, blood glucose, serum lipid levels and arterial blood pressure in obese patients

Background: Type 2 diabetes, hypertension and serum lipid abnormalities are common among obese people and they should improve with weight reduction. Aim: To study the outcome of these abnormalities after bariatric surgery in morbid obesity patients. Material and methods: Two hundred thirty two morbid obese patients subjected to gastric bypass, were evaluated in the preoperative period and every three months after surgery, during a minimum of 12 months. Clinical evolution, blood glucose, serum insulin, insulin resistance measured with the homeostasis model assessment (HOMA) and serum lipid levels were analyzed. Results: In the preoperative period, 17% had type 2 diabetes, 49% had abnormal serum lipid levels and 25% had high blood pressure. Sixty six percent had at least one of these abnormalities and 20% had more than one. During follow up, body mass index decreased from 44 to 29.3 kg/m2. Total and HDL cholesterol, blood glucose and insulin resistance significantly decreased from the third month after surgery. Diabetes disappeared in 97% of diabetic subjects, blood pressure normalized in 53% of subjects with hypertension and serum lipid levels returned to normal in 88% of subjects with dyslipidemia. Conclusions: Gastric bypass in morbid obese patients achieves a significant and important weight reduction that results in significant reductions in the frequency of diabetes, dyslipidemia and hypertension among operated obese subjects.

efficacy of dexmedetomidine in supressing cardiovascular and sympathoadrenal response to endotracheal intubation in hypertensive patients undergoing elective surgery

The present study was conducted on 20 controlled hypertensive adult patients. They all received general anesthesia for elective surgery and dexmedetomidine infusion for 5 minutes before endotracheal intubation and for 10 minutes thereafter. It was found out that there was a significant mild reduction in systolic blood pressure, mean heart rate, and rate pressure product after start of infusion, P=0.01, 0.05, and 0.01, respectively. After intubation, there were insignificant changes in systolic blood pressure [P=0.05] and heart rate showed mild significant increase at 1, 2, and 4 minutes with back to normal values at 6, 8, and 10 minutes. Rate pressure products also showed insignificant increase at 2, 4, and 6 minutes and back to normal at 6, 8 and 10 minutes. Epinephrine plasma level showed insignificant change after 10 minutes of intubation from baseline value 79.5 +/- 21 Vs. 76.8 +/- 18 pg/ml [P=0.01], while norepinephrine level was 419 +/- 48 pg/ml as baseline Vs. 428 +/- 51 pg/ml at 10 minutes after intubation with also mild insignificant change. The total dose of propofol used for induction of anesthesia was less than calculated as evidenced by loss of eyelash reflex and apnea with a mean value of 159 mg [1.54 mg/kg Bwt.] indicating that dexmedetomidine infusion before induction significantly reduced the dose of propofol needed for induction of anesthesia